AR048292A1 - Derivados de quinolina y composiciones farmaceuticas utiles para el tratamiento del cancer - Google Patents
Derivados de quinolina y composiciones farmaceuticas utiles para el tratamiento del cancerInfo
- Publication number
- AR048292A1 AR048292A1 ARP040104824A ARP040104824A AR048292A1 AR 048292 A1 AR048292 A1 AR 048292A1 AR P040104824 A ARP040104824 A AR P040104824A AR P040104824 A ARP040104824 A AR P040104824A AR 048292 A1 AR048292 A1 AR 048292A1
- Authority
- AR
- Argentina
- Prior art keywords
- cr10r11
- group
- alkyl
- heterocyclyl
- independently selected
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 125000004432 carbon atom Chemical group C* 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 5
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 101100240520 Caenorhabditis elegans nhr-14 gene Proteins 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 cyano, nitro, tetrazolyl Chemical group 0.000 abstract 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000000262 haloalkenyl group Chemical group 0.000 abstract 1
- 125000000232 haloalkynyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a las composiciones farmacéuticas que contienen los compuestos de formula (1) y a los procedimientos de tratamiento de trastornos hiperproliferativos en un mamífero. Reivindicacion 1: Un compuesto que tiene la estructura de la formula (1) en la que la ----- en la formula (1) indica un enlace opcional; el resto de formula (2) se selecciona entre el grupo constituido por los restos de formulas (3), la línea ----- indica un enlace opcional; X1 es un enlace o -C(O)NH-; X2 es O, S, o NR9 donde ----- no es un enlace, o X2 es N o CH donde ----- es un enlace; R9 es H o -CH3; R1a y R1b se seleccionan entre el grupo constituido por H, -(CR10R11)jCN, -(CR10R11)j-cicloalquilo C3-8, -(CR10R11)j-cicloalquenilo C5-8, alquenilo C2-6, alquinilo C2-6, -(CR10R11)j-arilo, -(CR10R11)j-heterociclilo, y alquilo C1-8, y donde los átomos de C de R1a y R1b se pueden sustituir opcionalmente con 1-3 grupos R12 seleccionados independientemente; R2a y R2b se seleccionan entre el grupo constituido por H, -CH3, -CF3, -CN, -CH2CH3, -OCH3, y -OCF3; R3 y R8 son independientemente F; X3 es O o NH; X5 es C donde ----- en la formula (1) es un enlace, o, donde ----- en la formula (1) no es un enlace, es CH o N; R4 y R7 se seleccionan independientemente entre H, halogeno, -CH3 y -CF3; R5 y R6 se seleccionan independientemente entre H, halogeno, -CF3, -N3, -NO2, -OH, -NH2, -OCF3, -X4(CR10R11)jCN, -X4(CR10R11)j-cicloalquilo C3-8, -X4(CR10R11)j-cicloalquenilo C5-8, -X4-alquenilo C2- 6, -X4-alquinilo C2-6, -X4(CR10R11)j-arilo, -X4(CR10R11)j-heterociclilo, heterociclilo, y -X4-alquilo C1-8, y donde los átomos de C y N de R5 y R6 se pueden sustituir opcionalmente con 1 a 3 grupos R13 seleccionados independientemente, o donde R5 y R6 tomados juntos pueden formar un resto cíclico seleccionado entre el grupo constituido por un carbociclilo de 4-10 eslabones y un heterociclilo de 4-12 eslabones que está opcionalmente sustituido con 1 a 3 grupos R13 seleccionados independientemente; X4 se selecciona entre el grupo constituido por un enlace, NH, -C(O)-, -NHC(O)-, -OC(O)-, -C(O)O-, -C(O)NH, y S; cada R10 y R11 se seleccionan independientemente entre el grupo constituido por H, F, y alquilo C1-6, o R10 y R11 tomados juntos pueden formar un carbociclilo, o dos grupos R10 unidos a átomos de C adyacentes se pueden seleccionar juntos para formar un carbociclilo; cada R12 y R13 se seleccionan independientemente entre el grupo constituido por halogeno, ciano, nitro, tetrazolilo, guanidino, amidino, metilguanidino, azido, -C(O)R14, -C(O), -CF3, -CF2CF3, -CH(CF3)2, -C(OH)(CF3)2, -OCF3, -OCF2H, -OCF2CF3, -OC(O)NH2, -OC(O)NHR14, -OC(O)NR14R15, -NHC(O)R14, -NHC(OH)NH2, -NHC(O)NHR14, -NHC(O)NR14R15, -C(O)OH, - C(O)OR14, -C(O)NH2, -C(O)NHR14, -C(O)NR14R15, -P(O)3H2, -P(O)3(R14)2, -S(O)3H, -S(O)mR14, -R14, -OR14, -OH, -NH2, -NH, -NHR14, -NR14, -NR14R15, -C(=NH)NH2, -C(NOH)NH2, -N-morfolino, alquilo C2-6, donde cualquiera de los átomos de C se pueden sustituir opcionalmente con un átomo de O, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, haloalquenilo C2-6, haloalquinilo C2-6, haloalcoxi C1-6, -(CR16R17)rNH2, -(CR16R17)rNHR14, -CR14R15, -(CR16R17)rNR14R15, y S(O)m(CF2)qCF3; o cualquier grupo de dos R12 o cualquiera de dos R13 unidos a átomos de C adyacentes se pueden seleccionar juntos para ser -O[C(R16)(R17)]rO- u -O[C(R16)(R17)]r+1-; o cualquier grupo de dos R12 o cualquiera de dos R13 unidos a los mismos o adyacentes átomos de C se pueden seleccionar juntos para formar un carbociclilo o heterociclilo; cada R14 y R15 se seleccionan independientemente entre el grupo constituido por alquilo C1-12, cicloalquilo C3-8, arilo C6-14, heterociclilo de 4-12 eslabones, -(CR10R11)j-arilo C6-10, y -(CR10R11)j-(heterociclilo de 4-12 eslabones); cada R16 y R17 se seleccionan independientemente entre el grupo constituido por H, alquilo C1-12, arilo C6-14, heterociclilo de 4-12 eslabones, -(CR10R11)j-arilo C6-10, y -(CR10R11)j- (heterociclilo de 4-12 eslabones); y donde cualquiera de los sustituyentes anteriormente mencionados comprendiendo un grupo CH3(metilo), CH2(metileno), o CH (metino) que no está unido a un grupo halogeno, SO o SO2 o a un átomo de N, O o S opcionalmente lleva sobre dicho grupo un sustituyente seleccionado entre el grupo constituido por hidroxi, halogeno, alquilo C1-4, alcoxi C1-4, y N[alquilo C1-4][alquilo C1-4]; y donde j es 0, 1, 2, o 3 y cuando j es 2 o 3, cada unidad CR10R11 puede ser la misma o diferente; y donde n es 0, 1, 2, o 3, y m es 0, 1 o 2; y donde q es un numero entero entre 0 y 5, y r es un numero entero entre 1 y 4; o un solvato farmacéuticamente aceptable o sal de los mismos farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53272503P | 2003-12-23 | 2003-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048292A1 true AR048292A1 (es) | 2006-04-19 |
Family
ID=34738830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040104824A AR048292A1 (es) | 2003-12-23 | 2004-12-21 | Derivados de quinolina y composiciones farmaceuticas utiles para el tratamiento del cancer |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US7381824B2 (es) |
| EP (1) | EP1699780A1 (es) |
| JP (1) | JP4503022B2 (es) |
| KR (1) | KR100807920B1 (es) |
| CN (1) | CN1890234A (es) |
| AP (1) | AP2006003619A0 (es) |
| AR (1) | AR048292A1 (es) |
| AU (1) | AU2004309166B2 (es) |
| BR (1) | BRPI0418102A (es) |
| CA (1) | CA2551508C (es) |
| CR (1) | CR8482A (es) |
| EA (1) | EA009994B1 (es) |
| EC (1) | ECSP066671A (es) |
| GE (1) | GEP20084572B (es) |
| GT (1) | GT200400274A (es) |
| HN (1) | HN2004000544A (es) |
| IL (1) | IL175947A (es) |
| IS (1) | IS8439A (es) |
| MA (1) | MA28396B1 (es) |
| MX (1) | MXPA06007242A (es) |
| MY (1) | MY139446A (es) |
| NL (1) | NL1027847C2 (es) |
| NO (1) | NO20063382L (es) |
| NZ (1) | NZ547009A (es) |
| OA (1) | OA13349A (es) |
| PE (1) | PE20050757A1 (es) |
| SG (1) | SG141459A1 (es) |
| TN (1) | TNSN06200A1 (es) |
| TW (1) | TWI331148B (es) |
| UA (1) | UA82577C2 (es) |
| UY (1) | UY28692A1 (es) |
| WO (1) | WO2005063739A1 (es) |
| ZA (1) | ZA200603657B (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20084572B (en) * | 2003-12-23 | 2008-12-25 | Pfizer | Novel quinoline derivatives |
| EP1711495A2 (en) * | 2004-01-23 | 2006-10-18 | Amgen Inc. | Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer |
| KR20080027923A (ko) * | 2005-08-08 | 2008-03-28 | 화이자 인코포레이티드 | Ｖｅｇｆ-ｒ 억제제의 염 및 다형체 |
| JP2009518382A (ja) * | 2005-12-05 | 2009-05-07 | ファイザー・プロダクツ・インク | Ｖｅｇｆ−ｒ阻害剤を調製する方法 |
| GB0604937D0 (en) * | 2006-03-10 | 2006-04-19 | Novartis Ag | Organic compounds |
| WO2008020302A2 (en) * | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| US8148532B2 (en) * | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
| US8163923B2 (en) * | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| PL2154967T3 (pl) | 2007-04-16 | 2014-08-29 | Hutchison Medipharma Entpr Ltd | Pochodne pirymidyny |
| US7829574B2 (en) | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
| CN101584696A (zh) * | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | 包含喹唑啉衍生物的组合物及制备方法、用途 |
| US8426430B2 (en) | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
| US8211911B2 (en) | 2008-08-19 | 2012-07-03 | Guoqing Paul Chen | Compounds as kinase inhibitors |
| US7737157B2 (en) | 2008-08-29 | 2010-06-15 | Hutchison Medipharma Enterprises Limited | Pyrimidine compounds |
| WO2010045095A1 (en) * | 2008-10-14 | 2010-04-22 | Ning Xi | Compounds and methods of use |
| IT1393351B1 (it) * | 2009-03-16 | 2012-04-20 | Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa | Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi |
| WO2010111063A1 (en) * | 2009-03-21 | 2010-09-30 | Ning Xi | Amino ester derivatives, salts thereof and methods of use |
| IN2012DN04917A (es) | 2009-11-05 | 2015-09-25 | Univ Notre Dame Du Lac | |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| EA023998B1 (ru) | 2011-03-04 | 2016-08-31 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Аминохинолины в качестве ингибиторов киназ |
| FR2973703A1 (fr) * | 2011-04-08 | 2012-10-12 | Univ Provence Aix Marseille 1 | Derives de 4-arylcoumarine et de 4-arylquinoleine, leurs utilisations therapeutiques et leur procede de synthese |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
| TWI592417B (zh) | 2012-09-13 | 2017-07-21 | 葛蘭素史克智慧財產發展有限公司 | 胺基喹唑啉激酶抑制劑之前藥 |
| AR092530A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| WO2014130612A1 (en) | 2013-02-20 | 2014-08-28 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| JP6301374B2 (ja) | 2013-02-21 | 2018-03-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | キナーゼ阻害剤としてのキナゾリン類 |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| CN103524409B (zh) * | 2013-09-26 | 2015-09-02 | 上海仁力医药科技有限公司 | 喹啉类化合物及其制备方法与应用 |
| CN105213394B (zh) * | 2014-06-06 | 2019-04-09 | 正大天晴药业集团股份有限公司 | 具有抗肿瘤活性的喹啉衍生物 |
| CN105311029A (zh) * | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 抗肿瘤活性的喹啉衍生物 |
| EP2974729A1 (en) * | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| CN104628686A (zh) * | 2015-01-27 | 2015-05-20 | 南通恒盛精细化工有限公司 | 一种带酰胺侧链的苯并呋喃制备工艺 |
| US10654808B2 (en) | 2015-04-07 | 2020-05-19 | Guangdong Raynovent Biotech Co., Ltd. | Tyrosine kinase inhibitor and pharmaceutical composition comprising same |
| US9890187B2 (en) | 2015-06-26 | 2018-02-13 | Epos-Iasis Research And Development, Ltd. | Prototype systems of theranostic biomarkers for in vivo molecular management of cancer |
| IL257743B (en) | 2015-09-17 | 2022-08-01 | Marvin J Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
| KR20180086187A (ko) | 2015-10-05 | 2018-07-30 | 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료 |
| CN110023288B (zh) | 2016-09-30 | 2022-10-28 | 广东众生睿创生物科技有限公司 | 酪氨酸激酶抑制剂的晶型、盐型以及制备方法 |
| CN107337634B (zh) * | 2017-08-28 | 2019-07-09 | 新发药业有限公司 | 一种阿贝西利中间体化合物的制备方法 |
| FR3080620B1 (fr) | 2018-04-27 | 2021-11-12 | Univ Paris Sud | Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices |
| KR20210151818A (ko) * | 2019-04-12 | 2021-12-14 | 내셔날 헬스 리서치 인스티튜트 | 치료 용도를 위한 키나제 억제제로서의 헤테로사이클릭 화합물 |
| WO2023138674A1 (zh) * | 2022-01-21 | 2023-07-27 | 默达药物（香港）有限公司 | N-羟基喹啉甲酰胺化合物及其用途 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE317376B (es) * | 1961-07-10 | 1969-11-17 | Roussel Uclaf | |
| FR2077455A1 (en) | 1969-09-03 | 1971-10-29 | Aries Robert | 5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials |
| US3755332A (en) * | 1971-07-01 | 1973-08-28 | Ciba Geigy Corp | Substituted 4 indazolaminoquinolines |
| US3936461A (en) * | 1973-09-24 | 1976-02-03 | Warner-Lambert Company | Substituted 4-benzylquinolines |
| FR2498187A1 (fr) * | 1981-01-16 | 1982-07-23 | Rhone Poulenc Sante | Procede de preparation d'amino-4 chloro-7 quinoleines |
| JPS62168137A (ja) * | 1985-12-20 | 1987-07-24 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料およびその処理方法 |
| IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| EP0586608A1 (en) | 1991-05-29 | 1994-03-16 | Pfizer Inc. | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
| JPH06504294A (ja) | 1991-08-02 | 1994-05-19 | ファイザー・インコーポレーテッド | 免疫刺激剤としてのキノリン誘導体 |
| GB9127252D0 (en) | 1991-12-23 | 1992-02-19 | Boots Co Plc | Therapeutic agents |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| KR100225721B1 (ko) | 1994-02-23 | 1999-10-15 | 디. 제이. 우드, 스피겔 알렌 제이 | 4-헤테로사이클릴-치환된 퀴나졸린 유도체, 이들의 제조 방법 및항암제로서의 용도 |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| TW321649B (es) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| ATE205483T1 (de) | 1995-03-30 | 2001-09-15 | Pfizer | Chinazolinderivate |
| DK0831829T3 (da) | 1995-06-07 | 2003-12-15 | Pfizer | Heterocykliske, ringkondenserede pyrimidinderivater |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| US6143764A (en) * | 1995-11-07 | 2000-11-07 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab, Soedertaelje | 4-anilinochinazolin derivate |
| AU2912997A (en) | 1996-06-24 | 1998-01-14 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| BR9709974A (pt) * | 1996-06-27 | 1999-08-10 | Pfizer | Derivados de 2-(2-oxo-etidileno)-imidazolidin-4-ona e seu uso como inibidores da transferase da proteina de farnesila |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| WO1998002437A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
| ATE300521T1 (de) | 1996-09-25 | 2005-08-15 | Astrazeneca Ab | Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern |
| US6225318B1 (en) * | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| KR20000057228A (ko) | 1996-11-27 | 2000-09-15 | 디. 제이. 우드, 스피겔 알렌 제이 | 축합된 비사이클릭 피리미딘 유도체 |
| EP1754703A3 (en) | 1997-02-19 | 2007-02-28 | Berlex, Inc. | N-Heterocyclic derivatives as nos inhibitors |
| ATE292623T1 (de) | 1997-05-07 | 2005-04-15 | Sugen Inc | 2-indolinonderivate als modulatoren der proteinkinase-ativität |
| EP0980258A1 (en) | 1997-05-12 | 2000-02-23 | The Kennedy Institute Of Rheumatology | Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy |
| CA2291709A1 (en) | 1997-05-30 | 1998-12-03 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| WO1999010349A1 (en) | 1997-08-22 | 1999-03-04 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
| AU744939B2 (en) | 1997-09-26 | 2002-03-07 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| ID23978A (id) | 1997-11-11 | 2000-06-14 | Pfizer Prod Inc | Turunan-turunan tienopirimidin dan tienopiridin yang berguna sebagai zat-zat anti kangker |
| JP4194678B2 (ja) | 1997-11-28 | 2008-12-10 | キリンファーマ株式会社 | キノリン誘導体およびそれを含む医薬組成物 |
| EP1086705A4 (en) | 1998-05-20 | 2002-02-06 | Kyowa Hakko Kogyo Kk | INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ACTIVITY |
| CO5031249A1 (es) | 1998-05-29 | 2001-04-27 | Sugen Inc | Pirrol substituido-2-indolinonas inhibidoras de proteinci-nasas |
| PT1117659E (pt) * | 1998-09-29 | 2004-04-30 | Wyeth Corp | Cianoquinolinas substituidas como inibidores de tirosina-quinases de proteinas |
| GB9827882D0 (en) | 1998-12-17 | 1999-02-10 | Smithkline Beecham Plc | Novel compounds |
| JP2002533404A (ja) | 1998-12-23 | 2002-10-08 | ジー・ディー・サール・アンド・カンパニー | 新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法 |
| ATE253051T1 (de) * | 1999-01-22 | 2003-11-15 | Kirin Brewery | Chinolinderivate und chinazolinderivate |
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| GB9904103D0 (en) | 1999-02-24 | 1999-04-14 | Zeneca Ltd | Quinoline derivatives |
| ES2238335T3 (es) | 1999-12-24 | 2005-09-01 | Kyowa Hakko Kogyo Co., Ltd. | Derivados de purina condensados. |
| US7135466B2 (en) * | 1999-12-24 | 2006-11-14 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives and drugs containing the same |
| EP1265635A1 (en) | 2000-03-22 | 2002-12-18 | Glaxo Group Limited | Pharmaceutical comprising an agent that blocks the cell cycle and an antibody |
| JP2004501070A (ja) | 2000-03-31 | 2004-01-15 | イムクローン システムズ インコーポレイティド | 血管内皮成長因子受容体アンタゴニストによる非固形哺乳類腫瘍の処理 |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| PT1297016E (pt) | 2000-05-12 | 2006-07-31 | Vlaams Interuniv Inst Biotech | Utilizacao de inibidores de factor de crescimento placentario para o tratamento da angiogenese patologica, da arteriogenese patologica, da inflamacao, da formacao de tumores e/ou das figas vasculares |
| MXPA03000252A (es) * | 2000-08-09 | 2003-06-06 | Astrazeneca Ab | Derivados de quinolina que tienen actividad de inhibicion de fcev. |
| KR100389127B1 (ko) | 2000-10-09 | 2003-06-25 | 동부한농화학 주식회사 | 벤조피라닐 헤테로고리 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물 |
| WO2002030453A1 (en) | 2000-10-12 | 2002-04-18 | Beth Israel Deaconess Medical Center, Inc. | Methods of inhibiting angiogenesis using nadph oxidase inhibitors |
| HU230302B1 (hu) * | 2000-10-20 | 2015-12-28 | Eisai R&D Management Co., Ltd. | Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények |
| ES2290199T3 (es) | 2000-11-22 | 2008-02-16 | Novartis Ag | Mezcla que incluye un agente que reduce la actividad de fcve y un agente que reduce la actividad de fce. |
| WO2002064170A1 (en) | 2001-02-09 | 2002-08-22 | Children's Medical Center Corporation | A method for treating cancer and increasing hematocrit levels |
| JP2005515967A (ja) | 2001-07-13 | 2005-06-02 | イムクローン システムズ インコーポレイティド | 乳癌を治療するためのｖｅｇｆｒ−１抗体 |
| EP1447405A4 (en) | 2001-10-17 | 2005-01-12 | Kirin Brewery | CHINOLIN OR CHINAZOLINE DERIVATIVES THAT PREVENT THE AUTOPHOSPHORYLATION OF RECEPTORS FOR THE FIBROBLAST GROWTH FACTOR |
| DK1441714T3 (da) | 2001-10-25 | 2008-03-31 | Novartis Ag | Kombinationer omfattende en selektiv cyclooxygenase-2-inhibitor |
| CA2478050A1 (en) * | 2002-03-01 | 2003-09-12 | Pfizer Inc. | Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents |
| KR100942073B1 (ko) | 2002-08-23 | 2010-02-12 | 기린 홀딩스 가부시키가이샤 | ＴＧＦ β 저해 활성을 갖는 화합물 및 그것을 포함하여 이루어지는 의약 조성물 |
| MXPA05001536A (es) | 2002-08-30 | 2005-04-19 | Eisai Co Ltd | Derivados aromaticos que contienen nitrogeno. |
| GEP20084572B (en) * | 2003-12-23 | 2008-12-25 | Pfizer | Novel quinoline derivatives |
-
2004
- 2004-12-13 GE GEAP20049472A patent/GEP20084572B/en unknown
- 2004-12-13 UA UAA200606997A patent/UA82577C2/uk unknown
- 2004-12-13 EA EA200600892A patent/EA009994B1/ru not_active IP Right Cessation
- 2004-12-13 AP AP2006003619A patent/AP2006003619A0/xx unknown
- 2004-12-13 CN CNA2004800361381A patent/CN1890234A/zh active Pending
- 2004-12-13 WO PCT/IB2004/004151 patent/WO2005063739A1/en not_active Ceased
- 2004-12-13 CA CA2551508A patent/CA2551508C/en not_active Expired - Fee Related
- 2004-12-13 BR BRPI0418102-6A patent/BRPI0418102A/pt not_active IP Right Cessation
- 2004-12-13 JP JP2006546363A patent/JP4503022B2/ja not_active Expired - Fee Related
- 2004-12-13 KR KR1020067012493A patent/KR100807920B1/ko not_active Expired - Fee Related
- 2004-12-13 AU AU2004309166A patent/AU2004309166B2/en not_active Ceased
- 2004-12-13 MX MXPA06007242A patent/MXPA06007242A/es active IP Right Grant
- 2004-12-13 NZ NZ547009A patent/NZ547009A/en not_active IP Right Cessation
- 2004-12-13 OA OA1200600212A patent/OA13349A/en unknown
- 2004-12-13 EP EP04801393A patent/EP1699780A1/en not_active Withdrawn
- 2004-12-13 SG SG200802320-2A patent/SG141459A1/en unknown
- 2004-12-16 US US11/015,508 patent/US7381824B2/en not_active Expired - Fee Related
- 2004-12-20 TW TW093139657A patent/TWI331148B/zh not_active IP Right Cessation
- 2004-12-21 AR ARP040104824A patent/AR048292A1/es not_active Application Discontinuation
- 2004-12-21 GT GT200400274A patent/GT200400274A/es unknown
- 2004-12-21 UY UY28692A patent/UY28692A1/es unknown
- 2004-12-22 MY MYPI20045319A patent/MY139446A/en unknown
- 2004-12-22 NL NL1027847A patent/NL1027847C2/nl not_active IP Right Cessation
- 2004-12-22 HN HN2004000544A patent/HN2004000544A/es unknown
-
2005
- 2005-01-03 PE PE2005000019A patent/PE20050757A1/es not_active Application Discontinuation
-
2006
- 2006-05-04 IS IS8439A patent/IS8439A/is unknown
- 2006-05-09 ZA ZA200603657A patent/ZA200603657B/xx unknown
- 2006-05-25 IL IL175947A patent/IL175947A/en not_active IP Right Cessation
- 2006-06-22 TN TNP2006000200A patent/TNSN06200A1/fr unknown
- 2006-06-22 CR CR8482A patent/CR8482A/es unknown
- 2006-06-23 MA MA29132A patent/MA28396B1/fr unknown
- 2006-06-23 EC EC2006006671A patent/ECSP066671A/es unknown
- 2006-07-21 NO NO20063382A patent/NO20063382L/no not_active Application Discontinuation
-
2008
- 2008-03-31 US US12/058,983 patent/US7923457B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR048292A1 (es) | Derivados de quinolina y composiciones farmaceuticas utiles para el tratamiento del cancer | |
| TW200643015A (en) | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives | |
| AR035260A1 (es) | Derivados de piperidina amino sustituidas, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de medicamentos como inhibidores de la gama secretasa, y para el tratamiento de la enfermedad de alzheimer | |
| AR086676A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa | |
| AR010378A1 (es) | Novedosos compuestos con efecto analgesico, uso de los mismos para la preparacion de un medicamento y como agente de diagnostico, composicion farmaceutica, proceso para la preparacion de dichos compuestos y compuestos intermediarios | |
| AR039659A1 (es) | Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasa | |
| AR067051A1 (es) | Indazoles sustituidos, su preparacion y su utilizacion terapeutica | |
| AR069326A1 (es) | Derivados bis-(sulfonilamino), proceso de preparacion, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| AR049956A1 (es) | DERIVADOS DE 1,3 - OXAZOLIDIN - 2 - ONA COMO INHIBIDORES DE CETP Y ELEVADORES DEL NIVEL DE LAD-C; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA ATEROSCLEROSIS. | |
| AR035371A1 (es) | Aminotiazoles, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento | |
| AR044514A1 (es) | Acidos carboxilicos alfa sustituidos como moduladores ppar | |
| AR080982A1 (es) | Derivados de quinoxalina | |
| AR060316A1 (es) | Azaindoles de utilidad como inhibidores de janus quinasas | |
| AR037329A1 (es) | Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos | |
| AR082994A1 (es) | Derivados de pirazina como bloqueadores del canal epitelial de sodio | |
| AR038179A1 (es) | Fenilsulfonamidas para uso terapeutico | |
| AR035235A1 (es) | Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento | |
| AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
| AR045040A1 (es) | Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos | |
| AR064414A1 (es) | Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que | |
| AR057408A1 (es) | Agonistas del receptor de niacina composiciones que contienen tales compuestos y procedimientos para tratamiento | |
| AR038835A1 (es) | Derivados de nicotinamida y una sal de tiotropio en combinacion para tratar enfermedades, el compuesto activo, una composicion farmaceutica que incluye la combinacion y uso de esta para la fabricacion de un farmaco | |
| AR031085A1 (es) | Compuestos inhibidores de la proteinasa c del procolageno, su uso en medicina, composiciones farmaceuticas que los contienen, procedimiento de fabricacion y compuestos utiles en la misma | |
| RU2012129887A (ru) | Ингибиторы мк2 | |
| AR054863A1 (es) | DERIVADOS DE 1H-PIRROLO[3, 4-C]PIRAZOL, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ASOCIADAS CON EL FACTOR DE COAGULACIoN XA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |